Advertisement
Screener

BeyondSpring Inc. (BYSI) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

BeyondSpring Inc. Research and Development Expense

BeyondSpring Inc. (BYSI) reported Research and Development Expense of $973.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14

  • BeyondSpring Inc. research and development expense for the quarter ending 2026-06-30 was $973.00K, a 2.89% decline year-over-year.
  • BeyondSpring Inc. research and development expense for the quarter ending 2026-03-31 was $1.08M, a 23.11% increase year-over-year.
  • BeyondSpring Inc. research and development expense for the quarter ending 2025-12-31 was $1.47M, a 212.08% increase year-over-year.
  • BeyondSpring Inc. research and development expense for the quarter ending 2025-09-30 was $1.04M, a 67.04% increase year-over-year.
  • BeyondSpring Inc. research and development expense for fiscal 2025 was $4.39M, a 65.96% increase from fiscal 2024.
  • BeyondSpring Inc. research and development expense for fiscal 2024 was $2.64M, a 63.64% decline from fiscal 2023.
  • BeyondSpring Inc. research and development expense for fiscal 2023 was $7.27M.
Period endResearch and Development Expense 3 monthResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 12 month
2026-06-30$973.00K
10-Q · filed 2026-08-14
$2.05M
10-Q · filed 2026-08-14
$3.52M
derived: sum of 3 quarters · filed 2026-08-14
$4.56M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31$1.08M
10-Q · filed 2026-05-13
$2.55M
derived: sum of 2 quarters · filed 2026-05-13
$3.59M
derived: sum of 3 quarters · filed 2026-05-13
$4.59M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31$1.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$2.51M
derived: sum of 2 quarters · filed 2026-03-25
$3.51M
derived: sum of 3 quarters · filed 2026-08-14
$4.39M
10-K · filed 2026-03-25
2025-09-30$1.04M
10-Q · filed 2025-11-12
$2.04M
derived: sum of 2 quarters · filed 2026-08-14
$2.92M
10-Q · filed 2025-11-12
$3.39M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30$1.00M
10-Q · filed 2026-08-14
$1.88M
10-Q · filed 2026-08-14
$2.35M
derived: sum of 3 quarters · filed 2026-08-14
$2.97M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31$874.00K
10-Q · filed 2026-05-13
$1.35M
derived: sum of 2 quarters · filed 2026-05-13
$1.97M
derived: sum of 3 quarters · filed 2026-05-13
$2.80M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$472.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$1.09M
derived: sum of 2 quarters · filed 2026-03-25
$1.92M
derived: sum of 3 quarters · filed 2026-03-25
$2.64M
10-K · filed 2026-03-25
2024-09-30$622.00K
10-Q · filed 2025-11-12
$1.45M
derived: sum of 2 quarters · filed 2025-11-12
$2.17M
10-Q · filed 2025-11-12
2024-06-30$829.00K
10-Q · filed 2025-08-13
$1.55M
10-Q · filed 2025-08-13
$4.15K
6-K · filed 2024-08-29
2024-03-31$721.00K
10-Q · filed 2025-05-12
2023-12-31$7.27M
10-K · filed 2025-03-27
2023-06-30$9.21K
6-K · filed 2024-08-29
$9.21M
6-K · filed 2024-02-02
2022-12-31$25.58M
20-F · filed 2023-04-18
2022-06-30$13.99M
6-K · filed 2024-02-02
2021-12-31$5.79M
derived: 20-F 12 month − 6-K 9 month · filed 2023-04-18
$14.24M
derived: sum of 2 quarters · filed 2023-04-18
$25.58M
derived: sum of 3 quarters · filed 2023-04-18
$36.89M
20-F · filed 2023-04-18
2021-09-30$8.46M
6-K · filed 2021-12-30
$19.79M
derived: sum of 2 quarters · filed 2021-12-30
$31.10M
6-K · filed 2021-12-30
$39.53M
derived: sum of 4 quarters · filed 2023-04-18
2021-06-30$11.33M
6-K · filed 2021-09-10
$22.64M
6-K · filed 2023-02-28
$31.07M
derived: sum of 3 quarters · filed 2023-04-18
$39.70M
derived: sum of 4 quarters · filed 2023-04-18
2021-03-31$11.31M
6-K · filed 2021-06-16
$19.73M
derived: sum of 2 quarters · filed 2023-04-18
$28.37M
derived: sum of 3 quarters · filed 2023-04-18
$39.40M
derived: sum of 4 quarters · filed 2023-04-18
2020-12-31$8.42M
derived: 20-F 12 month − 6-K 9 month · filed 2023-04-18
$17.06M
derived: sum of 2 quarters · filed 2023-04-18
$28.09M
derived: sum of 3 quarters · filed 2023-04-18
$41.79M
20-F · filed 2023-04-18
2020-09-30$8.64M
6-K · filed 2021-12-30
$19.66M
derived: sum of 2 quarters · filed 2021-12-30
$33.37M
6-K · filed 2021-12-30
$45.95M
derived: sum of 4 quarters · filed 2022-04-14
2020-06-30$11.03M
6-K · filed 2021-09-10
$24.73M
6-K · filed 2021-09-10
$37.31M
derived: sum of 3 quarters · filed 2022-04-14
$44.54M
derived: sum of 4 quarters · filed 2022-04-14
2020-03-31$13.70M
6-K · filed 2021-06-16
$26.28M
derived: sum of 2 quarters · filed 2022-04-14
$33.51M
derived: sum of 3 quarters · filed 2022-04-14
$38.72M
derived: sum of 4 quarters · filed 2022-04-14
2019-12-31$12.58M
derived: 20-F 12 month − 6-K 9 month · filed 2022-04-14
$19.81M
derived: sum of 2 quarters · filed 2022-04-14
$25.01M
derived: sum of 3 quarters · filed 2022-04-14
$31.34M
20-F · filed 2022-04-14
2019-09-30$7.23M
6-K · filed 2020-11-17
$12.43M
derived: sum of 2 quarters · filed 2020-11-17
$18.76M
6-K · filed 2020-11-17
$31.19M
derived: sum of 4 quarters · filed 2021-04-30
2019-06-30$5.20M
6-K · filed 2020-09-03
$11.53M
6-K · filed 2020-09-03
$23.96M
derived: sum of 3 quarters · filed 2021-04-30
$38.08M
derived: sum of 4 quarters · filed 2021-04-30
2019-03-31$6.33M
6-K · filed 2020-06-11
$18.76M
derived: sum of 2 quarters · filed 2021-04-30
$32.88M
derived: sum of 3 quarters · filed 2021-04-30
$43.87M
derived: sum of 4 quarters · filed 2021-04-30
2018-12-31$12.43M
derived: 20-F 12 month − 6-K 9 month · filed 2021-04-30
$26.55M
derived: sum of 2 quarters · filed 2021-04-30
$37.54M
derived: sum of 3 quarters · filed 2021-04-30
$51.62M
20-F · filed 2021-04-30
2018-09-30$14.12M
6-K · filed 2019-12-18
$25.12M
derived: sum of 2 quarters · filed 2019-12-18
$39.19M
6-K · filed 2019-12-18
$53.90M
derived: sum of 4 quarters · filed 2020-04-30
2018-06-30$10.99M
6-K · filed 2019-09-18
$25.07M
6-K · filed 2019-09-18
$39.77M
derived: sum of 3 quarters · filed 2020-04-30
$55.06M
derived: sum of 4 quarters · filed 2020-04-30
2018-03-31$14.07M
6-K · filed 2019-07-10
$28.78M
derived: sum of 2 quarters · filed 2020-04-30
$44.07M
derived: sum of 3 quarters · filed 2020-04-30
$56.26M
derived: sum of 4 quarters · filed 2020-04-30
2017-12-31$14.70M
derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30
$29.99M
derived: sum of 2 quarters · filed 2020-04-30
$42.18M
derived: sum of 3 quarters · filed 2020-04-30
$88.93M
20-F · filed 2020-04-30
2017-09-30$15.29M
6-K · filed 2017-11-09
$27.48M
derived: sum of 2 quarters · filed 2018-10-23
$74.22M
6-K · filed 2017-11-09
$77.25M
derived: sum of 4 quarters · filed 2019-04-30
2017-06-30$12.19M
6-K · filed 2018-10-23
$58.94M
6-K · filed 2018-10-23
$61.96M
derived: sum of 3 quarters · filed 2019-04-30
$64.70M
derived: sum of 4 quarters · filed 2019-04-30
2017-03-31$46.75M
6-K · filed 2018-06-21
$49.77M
derived: sum of 2 quarters · filed 2019-04-30
$52.51M
derived: sum of 3 quarters · filed 2019-04-30
$55.70M
derived: sum of 4 quarters · filed 2019-04-30
2016-12-31$3.02M
derived: 20-F 12 month − 6-K 9 month · filed 2019-04-30
$5.76M
derived: sum of 2 quarters · filed 2019-04-30
$8.95M
derived: sum of 3 quarters · filed 2019-04-30
$10.44M
20-F · filed 2019-04-30
2016-09-30$2.74M
6-K · filed 2017-11-09
$5.93M
derived: sum of 2 quarters · filed 2017-11-09
$7.41M
6-K · filed 2017-11-09
2016-06-30$3.19M
derived: 6-K 6 month − 6-K 3 month · filed 2017-08-21
$4.67M
6-K · filed 2017-08-21
2016-03-31$1.49M
6-K · filed 2017-05-22
2015-12-31$6.28M
20-F · filed 2018-04-03
2014-12-31$1.88M
20-F · filed 2017-04-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
NANOVIRICIDES, INC. (NNVC)United States$0.031B
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
Context Therapeutics Inc. (CNTX)United States$0.034B-1.10
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30